
China has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and policymakers around the world have gotten the message and know that this is no time for complacency. On a special edition of the BioCentury This Week podcast, BioCentury's analysts discuss why transformational reform for early clinical development will require rethinking the risk-control paradigm for first-in-human trials. It’s the subject of the...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick
Free AI-powered recaps of BioCentury This Week and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.